# Catheter Precision Partners With Two New German Heart Centers

- Published: 2026-11-16
- Author: [Healthcare News](https://healthcarenews.io/author/healthcarenews-io.md)
- Topics: [News](https://healthcarenews.io/news.md)
- Source: https://healthcarenews.io/news/catheter-precision-partners-with-two-new-german-heart-centers/
- Publication: Healthcare News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://healthcarenews.io/editorial-policy/

*VIVO Addresses Critical Need in Ventricular Ablations by Determining Targets with "GPS" Accuracy*

*Initial Procedure Demonstrated Desired Outcomes with Successful Ablation and Termination of Multiple Irregular Rhythms*

**FORT MILL, S.C., Nov. 16, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) --** Catheter Precision, a wholly owned subsidiary of Flyte Aviation, Inc. (NYSE American: VJET), today announced the successful completion of a clinical evaluation and its first commercial case in Germany at Klinikum Bayreuth.

Germany is the largest cardiology market in Europe and earlier this year, Catheter Precision partnered with a German distributor to expand its European footprint. After initially focusing on the company’s LockeT suture retention device, the distributor expanded its agreement to include the VIVO mapping system and scheduled two fourth-quarter evaluations in Germany.

Catheter Precision supported its first commercial procedure in the country, where VIVO demonstrated strong clinical value for the treating physicians. During the case, VIVO helped determine the optimal catheter approach, identified two distinct arrhythmia morphologies, and reduced overall procedure time while delivering successful patient outcomes.

“Completing our first commercial case in Germany at Klinikum Bayreuth is a major milestone that validates both the clinical impact of VIVO and our European expansion strategy,” said David Jenkins, CEO of Catheter Precision. “By helping physicians pinpoint distinct arrhythmia morphologies and significantly reduce procedure times, VIVO is proving its real-world value in the electrophysiology lab. As we convert these initial Q4 evaluations into recurring commercial adoption, we are building a scalable foundation for revenue growth and long-term shareholder value. We continue to believe that VIVO is the gateway to ventricular therapies in electrophysiology.”

**About VIVO**  
Catheter Precision's <a href="https://www.globenewswire.com/Tracker?data=X2p8kEjivWny2g8sGcfOyGCuLrzZ6MTb53jiS-e19NTgj-oMs3SQMzNQkElOb6M7bVLrRz5dYLqxi2c07PJfqNHJAvqiHF88oiMZ0UwfKFw=" rel="nofollow">VIVO</a>™ (View Into Ventricular Onset) is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias prior to an electrophysiology procedure, potentially streamlining procedural workflow. VIVO has received marketing clearance from the U.S. FDA and carries the CE Mark.

**About Catheter Precision**  
<a href="https://www.globenewswire.com/Tracker?data=-O8F1FOqcvaEiLUFphUXJyYd3h84s6Go3DdmFcgiceKjeja6WLDu-Z8IzUQPSRVyhlZBicGNGMcQd8wRUMhDO2zS9FfxQ4em5j-BylHXbmc3xsdI2qbAnpj0cAR-EoWCNHS-6P5OcKATNBydoUcNjjqVQoBkLbMH02OnIlhyATHGpGrMePA56W35TykEKtN9Rp-UaaA4XyJjw9me9iyayI_SwWxaWs8BHkC0rvQt1iOoCizMgU1Xq2cqBmeJEepqq__VJUE651rEgu8FajCbUA==" rel="nofollow">Catheter Precision</a> is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products. Catheter Precision is a wholly owned subsidiary of Flight Aviation, Inc., a NYSE/American listed company (VJET).

**Cautionary Note Regarding Forward-Looking Statements**  
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements regarding expected future growth, demand, strategic partnerships, market expansion, brand awareness, aircraft utilization and Flyte’s future operations, are forward-looking statements and involve risks and uncertainties that could cause actual results to differ materially. Readers are encouraged to review the Company’s filings with the Securities and Exchange Commission, including its Forms 10-K and 10-Q, for a discussion of these risks.

**Contact**  
<a href="https://www.globenewswire.com/Tracker?data=haThdW5X40CgprysFqvJmEeQCvqDTpg8z_aSKj5V0UNPEEtn_xLYMHuRlnbZaOvXDJrnBAA4aChcSl5UH7wJbfxVOnDDtZu9kLJ2aEgmFEY=" rel="nofollow">IR@FlyFlyte.com</a>  
(800) 763-0904

  
![](https://ml.globenewswire.com/media/NmVmNjRmNzItNGExMS00ZDBkLTk3MDUtYjY4ZmIzNTM0NzFjLTEzMDkxNDEtMjAyNi0xMS0xNi1lbg==/tiny/Flyte-Aviation-Inc-.png)

## Related

- [U.S. FDA Approves IGALMI® as First At-Home Acute Treatment for Agitation Associated with Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder in Adults](https://healthcarenews.io/news/u-s-fda-approves-igalmi-as-first-at-home-acute-treatment-for-agitation-associated-with-sch.md)
- [NewGen Provides Business Update](https://healthcarenews.io/news/newgen-provides-business-update.md)
- [Allarity Therapeutics Expands Phase 2 Stenoparib Trial to Three Ovarian Cancer Patient Cohorts](https://healthcarenews.io/news/allarity-therapeutics-expands-phase-2-stenoparib-trial-to-three-ovarian-cancer-patient-coh.md)
- [Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek® 2026](https://healthcarenews.io/news/corbus-pharmaceuticals-presents-phase-1b-canyon-1-clinical-trial-data-for-crb-913-at-obesi.md)
